This study aims to determine the levels of N-epsilon-(carboxymethyl)lysine (CML) in patients with Type 2 diabetic patients with and without ischemic heart disease (IHD) and to find for a possible association between circulating CML and a number of clinical parameters including lipids, hemoglobin Ale (HbA1c) and malondialdehyde (NIDA) in Type 2 diabetic 1111) patients. Serum CML levels were measured by enzyme-linked immunosorbent assay using polyclonal anti-CML antibodies. Serum levels of CML and NIDA were assessed in 60 IHD patients with Type 2 diabetes, 43 HID patients without Type 2 diabetes, 64 Type 2 diabetics without IHD, and 80 sex- and age-matched healthy subjects. Correlations studies between CML levels and lipids, HbA1c, and lipid peroxidation were performed in Type 2 diabetes patients with and without HID. A statistical significance was observed in the levels of serum glucose, lipids (triglyceride, total cholesterol, HDL-cholesterol), NIDA, HbA1c, CML and LDL-cholesterol (p<0.05) between the groups of the study. CML levels were significantly increased in diabetic IHD patients compared with Type 2 diabetes patients but without HID (537.1 86.1 vs 449.7 54.9, p<0.001). A positive correlation was observed between serum levels of CML and MDA, r= 0.338 (p = 0.008) in Type 2 diabetes patients with IHD. However, age, HbA1c and lipids had no significant influence on CML levels among diabetics (P>0.05). In conclusion, this study demonstrates the effect of both diabetes and oxidative stress on the higher levels of circulating CML. These results showed that increased serum levels of CML are associated with the development of HID in,Type 2 diabetes mellitus.
- advanced glycation end products,
- Type 2 diabetes mellitus,
- ischemic heart disease,
- oxidative stress
Available at: http://works.bepress.com/ikram_ismail/2/